NEWS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation

04/24/2025

Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy

04/10/2025

European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

04/09/2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

04/07/2025

Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications

03/31/2025

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference

02/26/2025

HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS

02/18/2025

Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results

02/04/2025

CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

02/03/2025

Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance

01/08/2025

View All Press Releases

All 3

All 3 /Company Updates 1 /Executive Insights 1 /Values Series 1

Insights Value Series: Introduction

April 5, 2022/by Wendy Wetherbee

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

August 9, 2021/by Wendy Wetherbee

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

January 28, 2021/by Wendy Wetherbee

Press Releases

05/21/21
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
05/10/21
Halozyme Reports First Quarter 2021 Results
04/29/21
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
04/20/21
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
02/24/21
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
02/23/21
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
02/23/21
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
02/10/21
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
01/15/21
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
01/11/21
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
01/04/21
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference